SCCA is one of the first cancer centers in the nation to offer five FDA-approved cellular immunotherapies. Axicabtagene ciloleucel (axi-cel), known by the brand name Yescarta®, brexucabtagene autoleucel, known by the brand name Tecartus™, and lisocabtagene maraleucel, known by the brand name Breyanzi® are CAR T-cell therapies available only at authorized treatment centers for non-Hodgkin lymphoma.
Tisagenlecleucel, known as the brand name Kymriah®,is a CAR T-cell therapy for non-Hodgkin lymphoma, as well as acute lymphoblastic leukemia.
Idecabtagene vicleucel, known by the brand name Abecma® is the newest CAR T-cell therapy available for multiple myeloma.
These CAR T-cell therapies are different from other cancer medicines because they are made from the patient's own white blood cells, which have been modified to recognize and attack the patient's cancer cells.